Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67

Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ 2010, Vol.341 (7774), p.c5396
Hauptverfasser: Desser, Arna S, Gyrd-Hansen, Dorte, Olsen, Jan Abel, Grepperud, Sverre, Kristiansen, Ivar Sønbø
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.c5396